Stockscreener 앱 받기
7.856
0.06%
-0.004
전일 마감가:
$7.86
열려 있는:
$8
하루 거래량:
35,533
Relative Volume:
0.23
시가총액:
$439.74M
수익:
$34.16M
순이익/손실:
$-98.43M
주가수익비율:
-2.8672
EPS:
-2.74
순현금흐름:
$-119.33M
1주 성능:
-10.74%
1개월 성능:
+8.64%
6개월 성능:
+26.29%
1년 성능:
+91.12%
1일 변동 폭
$7.73
$8.2451
1주일 범위
$7.33
$8.79
52주 변동 폭
$2.70
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
명칭
Foghorn Therapeutics Inc
전화
617-586-3100
주소
500 TECHNOLOGY SQUARE, CAMBRIDGE
FHTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| FHTX | 7.82 | 439.74M | 34.16M | -98.43M | -119.33M | -2.74 |
| VRTX | 450.61 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.05 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.41 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.93 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-03-28 | 개시 | BofA Securities | Buy |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-22 | 개시 | H.C. Wainwright | Buy |
| 2020-11-17 | 개시 | Cowen | Outperform |
| 2020-11-17 | 개시 | Goldman | Buy |
| 2020-11-17 | 개시 | Morgan Stanley | Overweight |
| 2020-11-17 | 개시 | Wedbush | Outperform |
모두보기
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
(FHTX) Technical Pivots with Risk Controls - Stock Traders Daily
Foghorn Therapeutics (FHTX) Collaborates with Eli Lilly and Surpasses Q3 Expectations - Nasdaq
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - The Manila Times
(FHTX) Trading Report - Stock Traders Daily
What is HC Wainwright’s Estimate for FHTX FY2024 Earnings? - Defense World
Wedbush Lifts Earnings Estimates for Foghorn Therapeutics - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think - Simply Wall St
Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter Report - Yahoo Finance
Research Analysts Issue Forecasts for FHTX FY2024 Earnings - MarketBeat
HC Wainwright Has Bullish Estimate for FHTX FY2024 Earnings - MarketBeat
We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully - Yahoo Finance
Foghorn Therapeutics Inc (FHTX) Q3 2024 Earnings: Revenue Surpas - GuruFocus.com
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Foghorn Therapeutics Reports Third Quarter Highlights - TipRanks
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update - GlobeNewswire
(FHTX) Investment Report - Stock Traders Daily
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Sold by Raymond James & Associates - Defense World
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk - Simply Wall St
Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Increases By 9.1% - MarketBeat
Long Term Trading Analysis for (FHTX) - Stock Traders Daily
Foghorn Therapeutics Unveils Clinical Pipeline Progress - Yahoo Finance
Foghorn Therapeutics Announces First Patient Dosed with - GlobeNewswire
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors - The Manila Times
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective - The Bakersfield Californian
FHTXFoghorn Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? - Yahoo Finance
Foghorn Therapeutics to Participate in the BMO Oncology Summit - GlobeNewswire
Perceptive Advisors LLC Purchases Shares of 544,000 Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Perceptive Advisors LLC Buys New Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - MarketBeat
Foghorn Therapeutics' SWOT analysis: chromatin biology pioneer's stock outlook By Investing.com - Investing.com UK
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Holdings Increased by Rhumbline Advisers - Defense World
Deerfield Management Company L.P. Series C Takes Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - MarketBeat
Deerfield Management Company L.P. Series C Purchases Shares of 2,518,500 Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics exec sells over $360k in company stock By Investing.com - Investing.com South Africa
Bank of New York Mellon Corp Buys 18,664 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics exec sells over $360k in company stock - Investing.com India
(FHTX) Long Term Investment Analysis - Stock Traders Daily
Foghorn Therapeutics (FHTX) Stock Forecast and Price Target 2024 - MarketBeat
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase - Benzinga
Foghorn Therapeutics (NASDAQ:FHTX) Price Target Raised to $9.00 - MarketBeat
Market Insight: Foghorn Therapeutics Inc (FHTX)’s Notable Gain, Closing at 9.99 - The Dwinnex
Foghorn Therapeutics exec sells over $116k in company stock By Investing.com - Investing.com Australia
Foghorn Therapeutics exec sells over $116k in company stock - Investing.com India
Foghorn Therapeutics executive sells over $107k in company stock By Investing.com - Investing.com Australia
Foghorn Therapeutics executive sells over $107k in company stock - Investing.com India
Foghorn Therapeutics Inc (FHTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):